Cyclic guanidines. IX. Synthesis of 2-amino-3,4-dihydroquinazolines as blood platelet aggregation inhibitors.

Synthesis and biological assessment of 2-hydroxyiminoethanones as anti-inflammatory and β-amyloid aggregation inhibitors

Alzheimer’s disease (AD) is a neuroinflammatory based pathologic state in which β-amyloid aggregates are a major devastating agents. In this study, a series of 2-hydroxyiminoethanones were synthesized and evaluated as anti-inflammatory in carrageenan and formalin tests and inhibitors of β-amyloid aggregation. Compounds 1-10b were synthesized through a two-step reaction. Results: Compounds 1-5b ...

Synthesis and biological assessment of 2-hydroxyiminoethanones as anti-inflammatory and β-amyloid aggregation inhibitors

Alzheimer’s disease (AD) is a neuroinflammatory based pathologic state in which β-amyloid aggregates are a major devastating agents. In this study, a series of 2-hydroxyiminoethanones were synthesized and evaluated as anti-inflammatory in carrageenan and formalin tests and inhibitors of β-amyloid aggregation. Compounds 1-10b were synthesized through a two-step reaction. Results: Compounds 1-5b ...

synthesis and biological evaluation of new indole hydrazone derivatives as platelet aggregation inhibitors

Design and Synthesis of RGD Mimetics as Potent Inhibitors of Platelet Aggregation

Vascular diseases, such as heart attacks and strokes, are known to be caused by the aggregation of platelets which form clots within blood vessels. These diseases can be prevented through the use of drugs that inhibit platelet aggregation by blocking a key platelet receptor, GPIIb/IIIa. The recognition of the arginine-glycine-aspartic acid (RGD) amino acid sequence by this receptor has been exp...

Cyclooxygenase-2 inhibitors enhance shear stress-induced platelet aggregation.

OBJECTIVES We aimed to investigate the effect of parecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, on in vivo shear stress-induced platelet aggregation in a rat model of arterial bypass with focal narrowing. BACKGROUND Long-term use of COX-2 inhibitors is associated with increased incidence of adverse cardiovascular events, especially in patients with a history of cardiovascular dise...